登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>MMAE >MME-MY2198a

Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) (MALS verified)

抗体来源(Source)

Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.

克隆号(Clone)

M1H05

种属(Species)

Rabbit

亚型(Isotype)

Rabbit IgG | Rabbit Kappa

偶联(Conjugate)

Unconjugated

抗体类型(Antibody Type)

Recombinant Monoclonal

免疫原(Immunogen)

MMAE-BSA.

特异性(Specificity)

Specifically recognizes MMAE, no recrecognizes MMAF.

应用(Application)

ApplicationRecommended Usage
ELISA0.03-31 ng/mL

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

纯化(Purification)

Protein A purified / Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

交叉验证(Cross Verification)

This product No cross-reactivity in ELISA with
Trastuzumab Deruxtecan.
Trastuzumab-DM1.
Trastuzumab Biosimilar.

 

电泳(SDS-PAGE)

MMAE SDS-PAGE

Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

MMAE SEC-MALS

The purity of Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) (Cat. No. MME-MY2198a) is more than 90% and the molecular weight of this protein is around 135-165 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

MMAE ELISA

Immobilized Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) (Cat. No. MME-MY2198a) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 100% Human Serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

Protocol

MMAE ELISA

Immobilized Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) (Cat. No. MME-MY2198a) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 0.5% BSA and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Protocol

MMAE ELISA

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) (Cat. No. MME-MY2198a) with a linear range of 0.06-2 ng/mL (Routinely tested).

Protocol

MMAE ELISA

Serial dilutions of Monomethyl auristatin E were added into Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) (Cat. No. MME-MY2198a): Disitamab Vedotin (RC48) binding reactions. The half maximal inhibitory concentration (IC50) is 2.642 μg/mL (Routinely tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Monomethyl auristatin E (MMAE) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several cancer types. Anti-MMAE antibody is a rabbit monoclonal antibody. The anti-MMAE antibody is a useful reagent in PK assay to determine conjugated antibodies.

 

前沿进展

Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer
Sternschuss, Rosenberg
Future Oncol (2025)
Abstract: Combination treatment with Enfortumab vedotin (EV), an antibody drug conjugate targeting Nectin-4 with a monomethyl auristatin E (MMAE) payload, and pembrolizumab, a programmed death 1 (PD-1) inhibitor, has become the new standard of care for previously untreated locally advanced or metastatic urothelial carcinoma. In the recently published phase III study, EV-302, EV and pembrolizumab demonstrated improved outcomes compared to platinum-based chemotherapy, including objective response rate, progression free survival, and an unprecedented median overall survival of 33.8 months (versus 15.9 months; hazard ratio for death 0.51; 95% confidence interval 0.43-0.61; p < 0.00001). We reviewed the mechanism of action, clinical efficacy, exploratory biomarkers, and safety profile of EV and pembrolizumab as monotherapies and combination in urothelial cancer.
Use of Spinosum Roentgen Index (S.R.I.) to determine candidacy for middle meningeal artery embolization
Sozio, Holliday, Hallman et al
Clin Imaging (2025) 121, 110457
Abstract: Middle meningeal artery embolization (MMAe) is a minimally-invasive approach for the treatment of subdural hematomas (SDH). Small vessel caliber and ectopic origin of the middle meningeal artery (MMA) may lead to unsuccessful embolization and/or serious morbidity. Thus, use of an objective scale to pre-procedurally assess candidacy for MMA embolization is an essential component of operative planning.A retrospective analysis of all patients having undergone MMAe across 4 years at a single institution was performed.169 MMAe procedures were performed for SDH, of which 3 were found to have a foramen spinosum diameter, termed the "Spinosum Roentgen Index" (SRI), measuring <2 mm on pre-procedure non-contrast CT Head. A statistically-significant correlation was found between foramen spinosum diameter <2 mm and unsuccessful embolization.Assessment of foramen spinosum diameter (Spinosum Roentgen Index (SRI)) may increase suspicion for aberrant MMA anatomy when measuring <2 mm, which can serve as valuable data in assessing risk versus benefit of MMA embolization, and ultimately minimize unexpected intraprocedural or immediate postprocedural complications.Copyright © 2025. Published by Elsevier Inc.
Prognostic significance of frailty in chronic subdural hematoma: implications for treatment selection in the era of middle meningeal artery embolization
J Dicpinigaitis, Kocharian, Covell et al
Neuroradiology (2025)
Abstract: Middle meningeal artery embolization (MMAE) as a standalone or adjunctive therapy has emerged as an efficacious and safe treatment for chronic/subacute subdural hematoma (csaSDH). The objective of this study is to compare the prognostic significance of frailty in csaSDH patients treated with MMAE alone or with craniotomy/burr hole (CBH).Hospitalization records were identified in the National Inpatient Sample (2016-2020) and the cohort was stratified by increasing frailty thresholds, quantified by the Risk Analysis Index (RAI). Effect sizes of frailty tiers for poor outcome (defined as non-routine discharge disposition) produced from multivariable logistic regression models and discrimination (c-statistic) were evaluated separately in the MMAE only and CBH sub-cohorts.This analysis identified 13,390 csaSDH hospitalizations, of which 595 (5%) documented treatment with MMAE only. Although all frailty tiers of the categorical RAI were significantly associated with poor outcome in the CBH cohort, lower effect sizes were observed in the MMAE cohort. Discrimination of RAI for poor outcome was significantly greater in the CBH cohort compared to the MMAE only cohort.In comparison to surgical evacuation, frailty demonstrated lower effect sizes and worse discrimination for poor outcomes in patients treated with MMAE, suggesting that frail patients may be more likely to achieve better outcomes following this less invasive therapy. MMAE may be considered as a first-line or standalone treatment in certain patients.© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Best practice in the use of middle meningeal artery embolisation for chronic subdural haematoma
Rickard, Backhouse, Langberg et al
Age Ageing (2025) 54 (3)
Abstract: Chronic subdural haematoma (cSDH) is a common neurosurgical disorder in older people and projected to become the most common cranial neurosurgical pathology by 2030. Incidence of cSDH has risen in recent years as a consequence of improved access to brain imaging, and the increased prescribing of antithrombotic medication for both primary and secondary prevention of vascular disease. Chronic SDH typically presents with an insidious onset of broad-ranging symptoms including impaired cognition, gait, balance and mobility, often with headache. It progresses to more fulminant symptoms of hemiplegia, dysphasia and eventually coma. Although the established standard of care for clearly symptomatic cSDH is burr hole trephination, Middle Meningeal Artery Embolisation (MMAE) has emerged as a minimally invasive treatment option for some patients with cSDH. This is a rapidly evolving field: recently published randomised control trials have provided an evidence-base supporting the use of MMAE not only as an adjunct to burr hole trephination, but also in patients in whom trephination is contraindicated, or in patients with mild symptomatology who are not considered appropriate for immediate burr hole trephination. This article provides practical, real-world guidance on current best practice based on our experience and the published evidence available to date. We use case studies and treatment algorithms from the UK's highest volume MMAE centre to illustrate collaborative care pathways for patients with cSDH between neurosurgery, interventional neuroradiology and trauma geriatricians.© The Author(s) 2025. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Showing 1-4 of 710 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细
相关产品
View All MMAE

消息提示

请输入您的联系方式,再点击提交!

确定